Dendritic cells are key orchestrators of the immune response, but most vaccination strategies don’t effectively target them. NIBIB-funded researchers have developed biodegradable nanoparticles that are designed to deliver mRNA cargo to dendritic cells in the spleen. Combined with another type of immunotherapy, their vaccine had robust antitumor effects in multiple mouse models.
